These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22886031)

  • 1. Tolerability of HIV integrase inhibitors.
    Lee FJ; Carr A
    Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of integrase inhibitors in a real-life setting.
    Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
    J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
    Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
    Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
    Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
    J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
    Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
    HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
    Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E
    Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of HIV integrase inhibitors.
    Adams JL; Greener BN; Kashuba AD
    Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
    Elliot E; Chirwa M; Boffito M
    Curr Opin Infect Dis; 2017 Feb; 30(1):58-73. PubMed ID: 27798496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect.
    Yombi JC
    AIDS Rev; 2018; 20(1):14-26. PubMed ID: 29628511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV pharmacotherapy: A review of integrase inhibitors.
    Wong E; Trustman N; Yalong A
    JAAPA; 2016 Feb; 29(2):36-40. PubMed ID: 26818644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
    Abo YN; Refsum E; Mackie N; Lyall H; Tudor-Williams G; Foster C
    Clin Drug Investig; 2019 Jun; 39(6):585-590. PubMed ID: 30976998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.
    Cottrell ML; Hadzic T; Kashuba AD
    Clin Pharmacokinet; 2013 Nov; 52(11):981-94. PubMed ID: 23824675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of HIV-1 integrase inhibitors in antiretroviral naive patients.
    Lennox JL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):409-14. PubMed ID: 22789985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation integrase inhibitors : where to after raltegravir?
    Karmon SL; Markowitz M
    Drugs; 2013 Mar; 73(3):213-28. PubMed ID: 23413196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.
    White KL; Raffi F; Miller MD
    Viruses; 2014 Jul; 6(7):2858-79. PubMed ID: 25054884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.